Holger N. Lode

7.2k total citations
202 papers, 4.8k citations indexed

About

Holger N. Lode is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Holger N. Lode has authored 202 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Neurology, 71 papers in Molecular Biology and 66 papers in Oncology. Recurrent topics in Holger N. Lode's work include Neuroblastoma Research and Treatments (106 papers), Cancer therapeutics and mechanisms (29 papers) and Immunotherapy and Immune Responses (29 papers). Holger N. Lode is often cited by papers focused on Neuroblastoma Research and Treatments (106 papers), Cancer therapeutics and mechanisms (29 papers) and Immunotherapy and Immune Responses (29 papers). Holger N. Lode collaborates with scholars based in Germany, United States and Austria. Holger N. Lode's co-authors include Ralph A. Reisfeld, Stephen D. Gillies, Rong Xiang, Nissi Varki, Doron Shabat, Gerhard Gaedicke, Carrie S. Dolman, Nikolai Siebert, Nicole Huebener and Marina Shamis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Investigation.

In The Last Decade

Holger N. Lode

191 papers receiving 4.7k citations

Peers

Holger N. Lode
D. Niethammer Germany
Eugenie S. Kleinerman United States
E. Anders Kolb United States
Qun Lin China
Dominic W. Chung United States
Richard Lake Australia
Tsutomu Tsuji Japan
Mary M. Tomayko United States
Tatsuji Yasuda Japan
Rainer Wiewrodt Germany
D. Niethammer Germany
Holger N. Lode
Citations per year, relative to Holger N. Lode Holger N. Lode (= 1×) peers D. Niethammer

Countries citing papers authored by Holger N. Lode

Since Specialization
Citations

This map shows the geographic impact of Holger N. Lode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger N. Lode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger N. Lode more than expected).

Fields of papers citing papers by Holger N. Lode

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger N. Lode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger N. Lode. The network helps show where Holger N. Lode may publish in the future.

Co-authorship network of co-authors of Holger N. Lode

This figure shows the co-authorship network connecting the top 25 collaborators of Holger N. Lode. A scholar is included among the top collaborators of Holger N. Lode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger N. Lode. Holger N. Lode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wieczorek, Aleksandra, et al.. (2025). Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma. Targeted Oncology. 20(4). 551–568. 3 indexed citations
2.
Lode, Holger N., et al.. (2024). A New Class of Gold(I) NHC Complexes with Proapoptotic and Resensitizing Properties towards Multidrug Resistant Leukemia Cells Overexpressing BCL-2. Journal of Medicinal Chemistry. 67(17). 15494–15508. 6 indexed citations
3.
Siebert, Nikolai, et al.. (2023). Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers. 15(13). 3317–3317. 8 indexed citations
4.
Wieczorek, Aleksandra, et al.. (2023). Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network. Healthcare. 11(10). 1431–1431. 4 indexed citations
5.
Ebinger, Martin, Ruth Ladenstein, Thorsten Simon, et al.. (2023). Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse. Journal of Clinical Medicine. 12(19). 6196–6196. 4 indexed citations
6.
Langner, Sönke, et al.. (2023). Quantitative Diffusion-Weighted MRI of Neuroblastoma. Cancers. 15(7). 1940–1940. 3 indexed citations
7.
8.
Siebert, Nikolai, et al.. (2022). The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers. 14(19). 4842–4842. 7 indexed citations
9.
Marx, Sascha, Lea Miebach, Sandra Bien-Möller, et al.. (2022). Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients. Cancers. 14(23). 5751–5751. 6 indexed citations
10.
Wieczorek, Aleksandra, Carla Manzitti, Alberto Garaventa, et al.. (2022). Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers. 14(8). 1919–1919. 12 indexed citations
11.
12.
Marx, Sascha, Isabel Viola Wagner, Joerg Baldauf, et al.. (2020). GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of Neuro-Oncology. 147(3). 577–585. 18 indexed citations
13.
14.
15.
Lode, Holger N., et al.. (2018). Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. PLoS ONE. 13(11). e0207320–e0207320. 5 indexed citations
16.
Siebert, Nikolai, Karoline Ehlert, Juliet C. Gray, et al.. (2018). Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers. 10(10). 387–387. 14 indexed citations
17.
Siebert, Nikolai, et al.. (2017). PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. OncoImmunology. 6(10). e1343775–e1343775. 51 indexed citations
18.
Ehlert, Karoline, Nikolai Siebert, Silke Kietz, et al.. (2017). Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs. 10(1). 55–61. 52 indexed citations
19.
Eggert, Angelika, et al.. (2012). Smac Mimetic LBW242 Sensitizes XIAP-Overexpressing Neuroblastoma Cells for TNF-α–Independent Apoptosis. Cancer Research. 72(10). 2645–2656. 38 indexed citations
20.
Huebener, Nicole, et al.. (2008). A novel legumain DNA vaccine effectively eradicates neuroblastoma and induces long-term survival in vivo. Cancer Research. 68. 2868–2868. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Niethammer Breakdown of academic impact, for papers by Eugenie S. Kleinerman Breakdown of academic impact, for papers by E. Anders Kolb Breakdown of academic impact, for papers by Qun Lin Breakdown of academic impact, for papers by Dominic W. Chung Breakdown of academic impact, for papers by Richard Lake Breakdown of academic impact, for papers by Tsutomu Tsuji Breakdown of academic impact, for papers by Mary M. Tomayko Breakdown of academic impact, for papers by Tatsuji Yasuda Breakdown of academic impact, for papers by Rainer Wiewrodt
Rankless by CCL
2026